Christopher Chi-Kit Cheng - 03 Aug 2026 Form 4 Insider Report for Cardlytics, Inc. (CDLX)

Reporting relationship: Chief Legal & Privacy Officer
Issuer ticker: CDLX
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 19:01:37 UTC
Source filing: View source filing
Reporting owner signature: /s/ Chris Cheng

Key filing fact

Christopher Chi-Kit Cheng filed Form 4 for Cardlytics, Inc. (CDLX) on 04 Aug 2026.

Key facts

This page summarizes Christopher Chi-Kit Cheng's Form 4 filing for Cardlytics, Inc. (CDLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 19:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002147591 Primary reporting owner

Cheng Christopher Chi-Kit

Relationship: Chief Legal & Privacy Officer
Address: 675 PONCE DE LEON AVENUE NE, SUITE 4100, ATLANTA
Signature: /s/ Chris Cheng
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDLX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

The restricted stock units shall vest over a period of 24 months, with 25,000 shares vesting on September 1, 2027 and the remaining shares vesting quarterly over the subsequent 12 months, provided that the Reporting Person remains employed by the Issuer on such vesting dates.